As of the announcement, 90 of approximately 120 planned patients had been randomized at sites in the US, UK, Australia, Germany, Poland, Bulgaria, and Romania.1 The company described enrollment as ahead of schedule.1
Blinded week 12 FVC and safety observations
Among 24 patients with evaluable baseline and week 12 FVC data, 8 (33%) improved from baseline, 11 (46%) declined by 5.7% or less, and 5 (21%) declined by more than 5.7%.1 Using a 5% threshold, 18 patients (75%) improved or declined by less than 5%.1 Individual changes ranged from a gain of 338 mL to a decline of 349 mL.1
Key Takeaways
What is LTI-03?
LTI-03 is an investigational inhaled peptide derived from caveolin-1 biology, in development by Rein Therapeutics for IPF. It is not FDA approved.
What did the blinded RENEW data show?
Among 24 evaluable patients pooled across treatment and placebo arms, 33% had improved FVC at week 12, and no serious adverse events were assessed as treatment related.
When are unblinded RENEW results expected?
Rein Therapeutics expects to report unblinded topline data from the 24-week RENEW trial in 2027.
The 5.7% threshold was drawn from an external meta-analysis of placebo arms in IPF trials, and the company characterized it as descriptive rather than a validated measure of treatment response.1
As of the interim cutoff, no serious adverse events (AEs) were assessed as related to study treatment.1 AEs were mostly mild or moderate, cough was the most frequently reported, and 92% of enrolled participants remained on or had completed the study.1
"We remain committed to advancing the study toward completion and look forward to reporting unblinded topline data in 2027," said Brian Windsor, PhD, president and chief executive officer, Rein Therapeutics.
Rein expects its current cash to fund operations into the first quarter of 2028, through completion of RENEW.1 The FDA lifted a clinical hold on LTI-03 in October 2025.1
References
Rein Therapeutics. Rein Therapeutics announces preliminary blinded phase 2 RENEW data showing encouraging lung function trends in patients with idiopathic pulmonary fibrosis and reports third quarter 2026 financial results. Published November 16, 2026. Accessed November 16, 2026. https://investors.aileronrx.com/news-releases/news-release-details/rein-therapeutics-announces-preliminary-blinded-phase-2-renew